Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity

Abstract

Development of cancer receptor-specific gold nanoparticles will allow efficient targeting/optimum retention of engineered gold nanoparticles within tumors and thus provide synergistic advantages in oncology as it relates to molecular imaging and therapy. Bombesin (BBN) peptides have demonstrated high affinity toward gastrin-releasing peptide (GRP) receptors in vivo that are overexpressed in prostate, breast, and small-cell lung carcinoma. We have synthesized a library of GRP receptor-avid nanoplatforms by conjugating gold nanoparticles (AuNPs) with BBN peptides. Cellular interactions and binding affinities (IC 50 ) of AuNP-BBN conjugates toward GRP receptors on human prostate cancer cells have been investigated in detail. In vivo studies using AuNP-BBN and its radiolabeled surrogate 198 AuNP-BBN, exhibiting high binding affinity (IC 50 in microgram ranges), provide unequivocal evidence that AuNP-BBN constructs are GRP-receptor-specific showing accumulation with high selectivity in GRP-receptor-rich pancreatic acne in normal mice and also in tumors in prostate-tumor-bearing, severe combined immunodeficient mice. The i.p. mode of delivery has been found to be efficient as AuNP-BBN conjugates showed reduced RES organ uptake with concomitant increase in uptake at tumor targets. The selective uptake of this new generation of GRP-receptor-specific AuNP-BBN peptide analogs has demonstrated realistic clinical potential in molecular imaging via x-ray computed tomography techniques as the contrast numbers in prostate tumor sites are severalfold higher as compared to the pretreatment group (Hounsfield unit = 150).gold nanoparticles | bombesin | gastrin-releasing peptide receptor | prostate cancer | computed tomography imaging

Gold nanoparticles induce nuclear damage in breast cancer cells, which is further amplified by hyperthermia

“…Their potential use in the field ranges from detection by imaging, labeling, or sensing [1][2][3][4][5] to treatment, including drug delivery and phototherapy [6][7][8][9][10][11][12][13][14].…”

Laminin receptor specific therapeutic gold nanoparticles ( 198 AuNP-EGCg) show efficacy in treating prostate cancer

“…We envisioned that radioactive gold nanoparticles, which are inherently therapeutic, present realistic prospects in achieving optimal therapeutic payloads in prostate tumors because of their (i) size, (ii) inherent affinity toward tumor vasculature, and (iii) most importantly, their favorable radiochemical properties (19)(20)(21). Au-198 provides a desirable beta energy emission and halflife that destroys tumor cells/tumor tissue (β max ¼ 0.96 MeV; half-life of 2.7 d) (18).…”

Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology

“…Human prostate tumors were xenografted into mice and the AuNP injected intraperitoneally to assess their ability to target a tumor in vivo. CT attenuation was found to be 4-fold higher within the tumor up to 6 hours after injection of particles [48]. Additionally, Angiopep-2, another tumor-targeting peptide, was used by Hao et al Poly(lactic glycolic acid) (PLGA) nanoparticles coated with Angiopep-2-functionalized AuNP were injected into a mouse and compared against untargeted particles.…”